Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

NCT02631954 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Aspergillus Infections
Candida Infections
Fungal Infections

Interventions

DRUG: Vorico Injection 200mg(Voriconazole)
DRUG: Vfend®(Voriconazole) IV 200mg

Sponsor

Chong Kun Dang Pharmaceutical